Cognitive Research Stack — Nootropic & Neurotrophic Combination
Reviewed by the BestHealingPeptides Editorial Team ·
Combine mechanistically distinct cognitive-enhancement peptides — BDNF/NGF upregulation (Semax), enkephalinase-mediated anxiolysis (Selank), and HGF/c-Met potentiation (Dihexa) — to explore the additive or synergistic effects of multi-pathway neurotrophic and behavioural modulation in pre-clinical research models.
Components
Protocol notes
This is a research-only stack. None of the components is licensed as a medicine in the UK. Combined administration to humans outside an authorised clinical-trial framework engages the Human Medicines Regulations 2012. Semax and Selank are registered prescription medicines in Russia for distinct indications; this does not authorise UK use. Dihexa is pre-clinical only with no human clinical-trial data. The combined protocol exists in research-chemical-community use but lacks formal Western RCT comparison of combined-versus-monotherapy pharmacology. Intranasal delivery for Semax and Selank; oral or parenteral delivery for Dihexa.
Mechanistic rationale — three distinct cognitive pathways
The cognitive research pharmacology space is organised around several distinct molecular pathways that can be addressed simultaneously through multi-component stacks. Semax addresses the BDNF/NGF/Trk axis through hippocampal neurotrophin upregulation — the conventional cognitive-enhancement pathway with the largest existing pre-clinical and clinical evidence base. Selank addresses the enkephalinase/GABA/serotonin axis through enzymatic inhibition and downstream monoamine modulation, producing non-sedating anxiolysis that complements rather than competes with Semax's nootropic activity. Dihexa addresses the entirely separate HGF/c-Met receptor signalling axis at femtomolar potency, driving dendritic-spine formation through a mechanism not shared with the BDNF/NGF compounds. The three peptides therefore engage three pharmacologically distinct molecular substrates, with no documented adverse interactions and plausible additive effects on the integrated cognitive phenotype. The mechanistic complementarity is the basis of legitimate combined research-protocol design.
Delivery considerations — multi-route stack management
Combined administration of Semax, Selank, and Dihexa requires managing multiple delivery routes simultaneously. Semax and Selank are intranasally delivered to exploit the olfactory and trigeminal pathways that bypass the blood-brain barrier — they can be co-reconstituted in compatible aqueous vehicles and co-administered intranasally in the same dosing schedule. Dihexa has meaningful oral bioavailability (~10-20% in rodents) and can be administered orally; whether oral Dihexa achieves clinically meaningful central exposure in humans is an open question pending human pharmacokinetic studies. Combined-stack research protocols typically use intranasal Semax + Selank twice or three times daily plus oral Dihexa once or twice daily, with timing coordination to maintain steady-state pharmacology across the three components. Cerebrolysin, the fourth cognitive-cluster compound, is not typically included in research-chemical-community combined-stack protocols given its multi-component preparation status, parenteral-only delivery requirement, and its standalone clinical-use framework in countries where it is registered.
Endpoint suggestions
Pharmacodynamic endpoints for cognitive research: hippocampal BDNF and NGF expression by ELISA or qRT-PCR in pre-clinical models; HGF/c-Met receptor phosphorylation in hippocampal tissue; dendritic spine density quantification by Golgi staining or two-photon imaging. Behavioural endpoints: Morris water maze and related spatial learning paradigms; novel object recognition; contextual fear conditioning; elevated plus maze and light/dark box for anxiolytic component characterisation. Electrophysiological endpoints: hippocampal CA3-CA1 long-term potentiation in slice preparations. Translational endpoints (where applicable): healthy-subject neuropsychological testing batteries (attention, working memory, processing speed, mood scales); for population-research contexts, validated cognitive assessment batteries (ADAS-Cog for Alzheimer's-related research, MoCA for general cognitive screening). The intranasal-route components (Semax, Selank) require pharmacodynamic timing that accounts for the 4-12 hour functional effect duration after each administration.
Where to source research peptides for laboratory research
The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.
- PeptideAuthority.co.uk
UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.
- PeptideBarn.co.uk
Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.